Helpful Resources

The following online gastroenterology resources may assist you, your staff and your patients.

Professional Associations
Gastroenterology Journals
Gastroenterology Links
Patient Resources

Shire US Inc. is permitting the links provided by the PENTASA® website to other websites as a service to its physicians and consumers. However, Shire US Inc. neither has nor assumes any responsibility or liability, either express or implied, for any such links or the accuracy or completeness of any information or service provided by any homepage or entity to which this homepage is linked.

The use of the links provided by this website is on an "as is" basis and at the user's sole risk. The links provided by this homepage are not intended to be and are not an endorsement of any service, product, or company position, nor do they necessarily reflect the views, philosophy, will, intent, or participation of Shire US Inc., its parent company, or any of its organizational entities.

Shire is not responsible for the content or services provided by any of these websites. The sites are not owned by Shire and are governed by their own policies and guidelines.

Important Safety Information

  • PENTASA is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.
  • PENTASA is generally well tolerated. In worldwide clinical trials (N>2100), the most common adverse events were diarrhea (3.4%), headache (2.0%), nausea (1.8%), abdominal pain (1.7%), dyspepsia (1.6%), vomiting (1.5%), and rash (1.0%). As with other mesalamine products, serious adverse events may occur. PENTASA is contraindicated in patients with a hypersensitivity to salicylates. Caution should be used in patients with impaired hepatic or renal function. Patients with pre-existing renal disease, increased BUN or serum creatinine, or proteinuria should be monitored during PENTASA therapy.